Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Core Insights - Merck's WINREVAIR (sotatercept-csrk) successfully met its primary endpoint in the Phase 2 CADENCE study targeting adults with chronic pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF) [1] Group 1 - The CADENCE study demonstrated significant efficacy of WINREVAIR in improving clinical outcomes for patients suffering from CpcPH related to HFpEF [1] - The results indicate a potential new treatment option for a patient population with limited existing therapies [1] - Merck's advancement in this area highlights the company's commitment to addressing unmet medical needs in cardiovascular diseases [1]